Chemokine receptors as therapeutic targets

Japanese Journal of Clinical Immunology

Volumn 36, Issue 4, 2013, Pages 189-196

  Yoshie, Osamu ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

CCR4; CCR5; Chemokine receptors; Chemokines; CXCR4

Indexed keywords

CHEMOKINE RECEPTOR; MARAVIROC; MOGAMULIZUMAB; PLERIXAFOR;

DENDRITIC CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; LYMPHOID CELL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, CCR4; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4;

EID: 84883330287     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.36.189     Document Type: Review

References (26)

1. Yoshie, O., et al.: Chemokines in immunity. Adv Immunol 78: 57-110, 2001.
2. Zlotnik, A., Yoshie, O.: The chemokine superfamily revisited. Immunity 36: 705-716, 2012.
3. McCully, M.L., Moser, B.: The human cutaneous chemokine system. Front Immunol 2: 1-15, 2011.
4. Imai, T., et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997.
5. Nakayama, T., et al.: Eotaxin-3/CC chemokine ligand 26 is a functional ligand for CX3CR1. J Immunol 185: 6472-6479, 2010.
6. Kroczek, R.A., Henn, V.: The role of XCR1 and its ligand XCL1 in antigen cross-presentation by murine and human dendritic cells. Front Immunol 3: 1-5, 2012.
7. Burger, E.A., et al.: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700, 1999.
8. Cocchi, F., et al.: Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressivve factors produced by CD8+ T cells. Science 270: 1811-1815, 1995.
9. Alkhatib, B., et al.: CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958, 1996.
10. Doranz, B.J., et al.: A dual-tropic HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158, 1996.
11. Baba, M., et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96: 5698-5703, 1999.
12. Maeda, K., et al.: CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerging Drugs 17: 135-145, 2012.
13. Fleishaker, D.L., et al.: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate eefficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res & Therapy 14: R11, 2012.
14. Peled, A., et al.: Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21: 341-353, 2012.
15. McDermott, D.H., et al.: The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 118: 4957-4962, 2011.
16. Fujisawa, T., et al.: Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 110: 139-146, 2002.
17. Horikawa, T., et al.: IFN-g-inducible expression of thymus and activation-regulated chemokine/CCL17 and macrophage-derived chemokine/CCL22 in epidermal keratinocytes and their roles in atopic dermatitis. Int Immunol 14: 767-773, 2002.
18. Saeki, H., Tamaki, K.: Thymus and activation-regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci 43: 75-84, 2006.
19. Yoshie, O., et al.: Frequent expression of CCR4 in adult T-cell leukemia and human Tcell leukemia virus type 1-transformed T cells. Blood 99: 1501-1511, 2002.
20. Ishida, T., et al.: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9: 3625-3634, 2003.
21. Nakayama, T., et al.: Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene 27: 3221-3232, 2008.
22. Higuchi, T., et al.: SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood 121: 3640-3649, 2013.
23. Imai, T., et al.: Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophagederived chemokine. Int Immunol 11: 81-88, 1999.
24. Yamamoto, K., et al.: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral Tcell lymphoma. J Clin Oncol 28: 1591-1598, 2010.
25. Ishida, T., et al.: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lympho, a: a multicenter phase II study. J Clin Oncol 30: 837-842, 2012.
26. Ishida, T., et al.: Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104: 647-650, 2013.